Clinical Trial Update: Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes the PREOPANC-5 study evaluating neoadjuvant triple therapy for localized or borderline resectable pancreatic adenocarcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING